Navigation Links
Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease
Date:4/10/2008

rest the progression of the disease. These symptomatic drugs are projected to generate approximately $4 billion in sales by 2008, indicating both the size of the market and the demand for effective treatment beyond symptomatic improvements.

About Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and other disorders. The company has a broad proprietary immunotherapy platform for both passive and active immunization against Alzheimer's disease. Also, Intellect has recently completed Phase I clinical trials for OXIGON(TM), a unique antioxidant and anti-amyloid compound that has potential to treat Alzheimer's disease and other disorders. For additional information, please visit http://www.intellectns.com, or contact:

Elliot Maza, JD, CPA

President & Chief Financial Officer

Intellect Neurosciences, Inc.

7 West 18th Street, 9th Floor

New York, NY 10011, USA

Tel: 212-448-9300

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Intellect relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward- looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
4. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
5. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
6. Amarin Secures Global Intellectual Property Rights for Lipid Programs
7. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
8. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
9. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
10. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
11. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015 /CNW/ - Resverlogix Corp. ... on RVX-208 was presented at the ERA-EDTA Congress in ... entitled: "Effects of RVX-208, a First-in-Class Epigenetic BET-Inhibitor, on ... CVD, and Chronic Kidney Disease (CKD); a Post-hoc Analysis ... Trials." Dr. Kam Kalantar-Zadeh , ...
(Date:6/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/lkcspr/2015_strategies ... "2015 Strategies in European Immunoprotein Diagnostic ... This new 273-page report provides ... including emerging tests, technologies, instrumentation, sales forecasts, ... suppliers. Companies Mentioned: - ...
(Date:6/1/2015)... DIEGO , June 1, 2015  OncoSec ... company developing DNA-based intratumoral cancer immunotherapies, today announced ... Davis) School of Veterinary Medicine to test ImmunoPulse™ ... tissue sarcoma. The primary goals of the canine ... mechanism of action of ImmunoPulse™ IL-12 and validate ...
(Date:6/1/2015)... 1, 2015 Hutchison China ... AstraZeneca AB (publ) ("AstraZeneca"), Hutchison MediPharma Limited,s ("HMP") ... Phase Ib clinical trial of HMP,s c-Met inhibitor ... in non-small cell lung cancer ("NSCLC"). ... growth factor receptor (EGFR). Preliminary data on the ...
Breaking Biology Technology:Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 2OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 3OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 4Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 3
... on the Comprehensive Microbial Resource enable researchers to quickly and effectively ... ... December 10, 2008 -- OpenHelix today announced the availability ... CMR is a public resource for the analysis of ...
... of growing computing power could be sustained for many ... the UK,s National Physical Laboratory (NPL) that is applying ... that the density of transistors on an integrated circuit ... to achieve this, but experts believed that when the ...
... Transgenomic, Inc.,(OTC Bulletin Board: TBIO) today announced that ... Commission on Laboratory Accreditation of the,College of American ... recent,on-site inspection. Transgenomic is now one of the ... Craig Tuttle, CEO of Transgenomic, said, "We are ...
Cached Biology Technology:New Online Tutorial for the Comprehensive Microbial Resource (CMR) 2Transgenomic Receives Accreditation From College of American Pathologists 2Transgenomic Receives Accreditation From College of American Pathologists 3
(Date:5/7/2015)... Fingerprint Cards (FPC) introduces ... FPC,s smallest touch fingerprint sensors to date.  ... integration on the backside of the phone, and ... to integrate touch fingerprint sensors in the OEMs, ... for module manufacturers to customize the look and ...
(Date:4/27/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® Smart ... week of May, 2015 and will be fulfilling all ... Gino Pereira , Chief Executive Officer said, ... Wocket® enters the consumer market. We would like to ...
(Date:4/20/2015)... The announcement comes as demand for fire vault ... Ireland,s foremost records management company, has secured ... impressive track record of clients within the first 12 months, ... sector in Dubai . As a result, ... a further eight staff members at its Irish headquarters. The ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... A major public symposium at Boston College will bring together ... the contributions of the physical and social sciences to a ... the Liberal Arts University Why It Matters to Us ... for the Liberal Arts, takes place today at the University,s ...
... still the primary treatment for halting the spread ... resistance is now outpacing the rate of new ... University of Wisconsin-Milwaukee (UWM) has discovered a different ... disarm them, quashing disease without the worry of ...
... A study led by Matej Oreič from ... autoimmune diabetes is preceded by diminished gut microbial ... leptin and enhanced glucose-stimulated insulin secretion. In ... Diabetes and Prediction study, VTT researches have previously ...
Cached Biology News:Science in the liberal arts university 2An antibiotic effect minus resistance 2An antibiotic effect minus resistance 3VTT identified specific bacteria which precede autoimmune diabetes 2
... Sepharose High Performance, 5 ml. The ... in HiTrap Streptavidin columns for fast, ... packing into Tricorn 5/50 GL, XK ... scale purifications are required.Extremely useful for ...
...
...
...
Biology Products: